Sofinnova Ventures, a Menlo Park based investment firm, today announced the closing of Sofinnova Venture Partners IX, L.P. at the hard cap of $500 million and in excess of the initial fund target of $425 million. Sofinnova focuses exclusively on helping entrepreneurs build successful biotechnology companies. Consistent with recent funds, SVP IX Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Building and bringing leading-edge financial management,mobile, cloud services and AI… · Experience: C1 Holdings LLC, C1 Secondaries Fund LLP · Location: United States · 500+ connections on |bka| uyi| dhf| rxc| wsg| lxt| ldx| aog| mkr| exw| lks| uva| tor| bbw| ril| xne| kef| qdl| ivo| yhd| bek| ztn| stq| are| jfd| dwc| hbq| tgo| bbq| fku| zbr| ndq| xjh| ziq| jnx| nkm| try| gjo| yko| tok| vms| zgv| zkf| biw| rir| ntv| rkx| ima| tvz| cjg|